The current state of antiplatelet therapy in acute coronary syndromes: the data and the real world.

Journal Article (Journal Article;Review)

Managing antiplatelet therapy for patients with acute coronary syndromes (ACS) is complex, and current therapy options and approaches for these patients are suboptimal. Despite the use of available antiplatelet therapies--aspirin, clopidogrel, and the parenteral glycoprotein IIb/IIIa inhibitors--recurrence of ischemic events in patients with ACS continues to rise over time. Moreover, bleeding remains an important--and often underappreciated--risk with these therapies, and national registries demonstrate that dosing of antiplatelet therapies frequently strays from evidence-based guidelines. Recent quality-improvement initiatives developed in conjunction with national registries of patients with ACS promise to improve adherence to guidelines through hospital-specific performance reports. More evidence-based use of existing and emerging antiplatelet agents has the potential to improve both ischemic and bleeding outcomes in patients with ACS.

Full Text

Duke Authors

Cited Authors

  • Alexander, JH

Published Date

  • April 2009

Published In

Volume / Issue

  • 76 Suppl 1 /

Start / End Page

  • S16 - S23

PubMed ID

  • 19332589

Electronic International Standard Serial Number (EISSN)

  • 1939-2869

Digital Object Identifier (DOI)

  • 10.3949/ccjm.76.s1.03


  • eng

Conference Location

  • United States